The impact of SARS-COV-2 on biomanufacturing operations
Name
BioPharm International.pdf
Description
Accepted version
Size
248.09 KB
Format
Adobe PDF
Checksum (MD5)
34fd1fa5dd32946f735fdfe3b25d6d09
Author(s)
Barone, Paul
Keumurian, Flora J.
Wiebe, Michael E
Wolfrum, Jacqueline M
Leung, JC
Sinskey, Anthony J
Springs, SL
Date Issued
January 2020
Journal
BioPharm International
Citation
Barone, Paul W. et al. "The impact of SARS-COV-2 on biomanufacturing operations." BioPharm International 33, 8 (January 2020): 34–38.
Version
Author's final manuscript
Abstract
The spread of COVID-19, which is caused by SARS-CoV-2, an enveloped, single-stranded RNA virus, was declared a global pandemic on March 11, 2020, and the virus has infected millions of individuals and led to hundreds of thousands of deaths. One of the main approaches used to mitigate the spread of the virus has been to institute stay-at-home orders and close all non-essential businesses. These closures do not include pharmaceutical and biopharmaceutical companies, which are conducting essential work to rapidly develop and manufacture new treatments and vaccines to fight the pandemic as well as continuing to provide a steady supply of life-saving medicines to patients.
MIT Department
Massachusetts Institute of Technology. Center for Biomedical Innovation
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://www.biopharminternational.com/view/the-impact-of-sars-cov-2-on-biomanufacturing-operations
